**Question:** Considering Brenner tumor all are true EXCEPT:

A. Brenner tumor is a rare tumor that develops from the cells of the ovary's cortex.
B. Brenner tumor is a type of cancerous tumor.
C. Brenner tumor is a type of mesothelioma.
D. Brenner tumor occurs predominantly in males.

**Core Concept:**
Brenner tumor is a rare tumor that primarily affects females, although it can occur in males as well. It develops from the cells of the ovary's cortex and is a benign tumor. Mesothelioma, on the other hand, is a malignant tumor that originates from mesothelial cells lining the pleura, pericardium, and peritoneum, and is a separate entity from Brenner tumor.

**Why the Correct Answer is Right:**
The correct answer is D, as Brenner tumor predominantly affects females, not males. Although it can occur in males, the statement is incorrect when referring to the general population. Brenner tumor is a benign tumor, so option B is incorrect. While Brenner tumor does develop from the cells of the ovary's cortex, option C is incorrect as it confuses it with mesothelioma, a completely different entity. Mesothelioma is a malignant tumor originating from mesothelial cells, whereas Brenner tumor is a benign tumor.

**Why Each Wrong Option is Incorrect:**
A. Although Brenner tumor is a rare tumor, the statement that it is a type of cancerous tumor is incorrect. Brenner tumor is a benign tumor.
B. As mentioned before, Brenner tumor is a benign tumor, not a cancerous one.
C. Brenner tumor originates from the cells of the ovary's cortex and is distinct from mesothelioma, which develops from mesothelial cells.

**Clinical Pearl:**
Brenner tumor is a low-grade tumor with a slow growth rate, typically diagnosed in middle-aged to elderly females. While it is generally considered a benign tumor, it can occasionally exhibit malignant potential and may require surgical excision for definitive diagnosis and treatment planning. It is essential for clinicians to differentiate it from other ovarian tumors like serous borderline tumors or clear cell carcinomas, as the management strategies differ significantly.